Is AbbVie Inc. Stock (ABBV) Overbought or Oversold?
RSI analysis computed from ABBV's daily closing prices · Data through July 2, 2026
As of July 2, 2026, ABBV’s 14-day RSI is 75.8, above the conventional overbought threshold of 70 — the stock has risen quickly relative to its recent trading range.
RSI-14 Scale
ABBV reads 75.8 on the 0–100 scale.
The Supporting Picture
vs 50-Day MA
+13.4%
MA: $224.70
vs 200-Day MA
+17.3%
MA: $217.27
From 52-Wk High
0.0%
High: $261.06
Volume vs 20-Day Avg
+0%
Avg: 4.6M shares
The 50-day average is currently above the 200-day average, which technicians read as a longer-term uptrend backdrop for the RSI reading above.
What's Behind the Reading
July 6, 2026AbbVie's stock has recently reached a 52-week high, contributing to its overbought RSI reading of 75.79. This strong momentum appears to be driven by several positive catalysts. A significant factor is the proposed new rule by the Trump administration to modify reimbursement rates under the 340B Drug Pricing Program, which is expected to shift financial margins in favor of major drug developers like AbbVie. This policy change is anticipated to enhance margin retention for manufacturers, sparking a rally across the pharmaceutical sector. Additionally, AbbVie's strategic acquisition of Apogee Therapeutics has been favorably received by Wall Street, viewed as a pivotal expansion of its immunology franchise. The FDA approval for Skyrizi's pediatric treatment also expands the drug's market reach, further bolstering investor confidence. Strong Q1 2026 results, driven by Skyrizi and Rinvoq, also solidified investor confidence in AbbVie's post-Humira strategy.
Recent Overbought / Oversold Episodes
How ABBV behaved the last few times RSI left the neutral band — including its return over the 5 trading days after each episode ended.
| Episode | Period | Next 5 Days |
|---|---|---|
| overbought | June 29, 2026 – July 2, 2026 | Ongoing |
| oversold | March 19, 2026 – March 24, 2026 | +5.4% |
| overbought | September 30, 2025 – October 1, 2025 | -5.4% |
| overbought | September 17, 2025 – September 23, 2025 | +4.0% |
Past behavior does not predict future results — small sample sizes especially.
Frequently Asked Questions
Is AbbVie Inc. (ABBV) overbought right now?
What is RSI (Relative Strength Index)?
Is an overbought stock a sell signal?
How often is this page updated?
Where does this data come from?
Methodology
The verdict on this page is mechanical: we compute the 14-day Relative Strength Index with Wilder’s smoothing from ABBV’s daily closing prices, and apply the conventional thresholds — above 70 is overbought, below 30 is oversold. Moving averages, the 52-week range, and volume comparisons come from the same price history.
Indicators are recomputed after every market close. The AI commentary adds context from current news via grounded search, but never changes the computed verdict. Note: closes are as-traded; a stock split would distort readings for a few weeks until the window rolls past it.
Not Financial Advice
This page is for education and information only. Indicators are mechanical calculations, AI commentary can contain errors, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a qualified financial advisor. See our full disclaimer.
Keep Digging on ABBV
AbbVie Inc. Overview
Price, chart, analysis & financials
ABBV: Why Is It Moving?
Updated daily
ABBV: Price Prediction
Updated daily
ABBV: Undervalued or Overvalued?
Updated daily
Same question, Healthcare peers